These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 14571082)

  • 1. Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign.
    Banka N; Aljurf M; Hamadah I
    Dermatology; 2003; 207(3):329-30. PubMed ID: 14571082
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.
    Vora A; Bhutani M; Sharma A; Raina V
    Ann Oncol; 2002 Nov; 13(11):1833-4. PubMed ID: 12419759
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib mesylate induced erythroderma.
    Sanghavi SA; Dongre AM; Khopkar US
    Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous Lichenoid dermatitis associated with imatinib mesylate.
    Chan CY; Browning J; Smith-Zagone MJ; Martinelli PT; Hsu S
    Dermatol Online J; 2007 May; 13(2):29. PubMed ID: 17498448
    [No Abstract]   [Full Text] [Related]  

  • 5. Generalized hypopigmentation due to imatinib: a fairness boon?
    Sharma A; Vora A; Bhutani M
    Indian J Dermatol Venereol Leprol; 2005; 71(1):45-6. PubMed ID: 16394363
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose.
    Pavithran K; Thomas M
    Indian J Dermatol Venereol Leprol; 2005; 71(4):288-9. PubMed ID: 16394445
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
    Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
    Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
    Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
    Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
    Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia.
    Barton JC; Jones SC; Lamberth WC; Reymann MT; Scott VC
    Am J Hematol; 2002 Oct; 71(2):139-40. PubMed ID: 12353320
    [No Abstract]   [Full Text] [Related]  

  • 12. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

  • 14. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
    Raanani P; Goldman JM; Ben-Bassat I
    J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
    Govind Babu K; Attili VS; Bapsy PP; Anupama G
    Int Ophthalmol; 2007 Feb; 27(1):43-4. PubMed ID: 17410337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect.
    Georgalas I; Pavesio C; Ezra E
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1585-6. PubMed ID: 17562067
    [No Abstract]   [Full Text] [Related]  

  • 18. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib.
    Saponara M; Di Battista M; Lolli C; Pantaleo MA; Azzaroli F; Santini D; Di Scioscio V; Catena F; Astorino M; Maleddu A; Biasco G
    Endoscopy; 2009; 41 Suppl 2():E67-8. PubMed ID: 19319786
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib and ruxolitinib association: first experience in two patients.
    Iurlo A; Gianelli U; Rapezzi D; Cattaneo D; Fermo E; Binda F; Santambrogio E; Bucelli C; Cortelezzi A
    Haematologica; 2014 Jun; 99(6):e76-7. PubMed ID: 24633869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.